PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
PIK3CA 突变与 HER2 阳性乳腺癌新辅助吡咯替尼和曲妥珠单抗联合化疗的病理完全缓解率相关
期刊:British Journal of Cancer
影响因子:6.4
doi:10.1038/s41416-022-02021-z
Qiyun Shi #, Juncheng Xuhong #, Tao Luo #, Jia Ge, Feng Liu, Yang Lan, Qingqiu Chen, Peng Tang, Linjun Fan, Li Chen, Yan Liang, Minghao Wang, Ying Hu, Yi Zhang, Xiuwu Bian, Xiaowei Qi, Jun Jiang
